Cumberland Pharmaceuticals (CPIX) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Cumberland Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$37.87M

Latest Revenue (Q)

$8.29M

Main Segment (Y)

Product

Main Geography (Y)

Non-US

Cumberland Pharmaceuticals Revenue by Period

Cumberland Pharmaceuticals Revenue by Year

Date	Revenue	Change
2024-12-31	$37.87M	-4.26%
2023-12-31	$39.55M	-5.85%
2022-12-31	$42.01M	16.75%
2021-12-31	$35.99M	-3.89%
2020-12-31	$37.44M	8.88%
2019-12-31	$34.39M	-15.59%
2018-12-31	$40.74M	-0.99%
2017-12-31	$41.15M	24.60%
2016-12-31	$33.03M	-1.47%
2015-12-31	$33.52M	-9.17%
2014-12-31	$36.90M	15.22%
2013-12-31	$32.03M	-34.44%
2012-12-31	$48.85M	-4.48%
2011-12-31	$51.14M	11.48%
2010-12-31	$45.88M	5.37%
2009-12-31	$43.54M	24.13%
2008-12-31	$35.08M	24.98%
2007-12-31	$28.06M	57.52%
2006-12-31	$17.82M	66.66%
2005-12-31	$10.69M	-

Cumberland Pharmaceuticals generated $37.87M in revenue during NA 2024, up -4.26% compared to the previous quarter, and up 110.12% compared to the same period a year ago.

Cumberland Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2025-09-30	$8.29M	-23.48%
2025-06-30	$10.84M	-7.48%
2025-03-31	$11.71M	12.24%
2024-12-31	$10.44M	14.86%
2024-09-30	$9.09M	-7.75%
2024-06-30	$9.85M	15.90%
2024-03-31	$8.50M	-9.15%
2023-12-31	$9.35M	-7.27%
2023-09-30	$10.09M	-7.37%
2023-06-30	$10.89M	18.04%
2023-03-31	$9.22M	1.11%
2022-12-31	$9.12M	-20.06%
2022-09-30	$11.41M	10.82%
2022-06-30	$10.30M	-7.84%
2022-03-31	$11.18M	34.32%
2021-12-31	$8.32M	3.06%
2021-09-30	$8.07M	-10.85%
2021-06-30	$9.06M	-14.06%
2021-03-31	$10.54M	2.69%
2020-12-31	$10.26M	10.93%
2020-09-30	$9.25M	-3.62%
2020-06-30	$9.60M	15.21%
2020-03-31	$8.33M	-39.10%
2019-12-31	$13.68M	31.88%
2019-09-30	$10.37M	-10.44%
2019-06-30	$11.58M	-2.71%
2019-03-31	$11.90M	-11.82%
2018-12-31	$13.50M	58.94%
2018-09-30	$8.49M	-16.44%
2018-06-30	$10.16M	18.35%
2018-03-31	$8.59M	-26.28%
2017-12-31	$11.65M	4.04%
2017-09-30	$11.20M	29.19%
2017-06-30	$8.67M	-10.06%
2017-03-31	$9.64M	6.11%
2016-12-31	$9.08M	3.29%
2016-09-30	$8.79M	18.57%
2016-06-30	$7.41M	-4.17%
2016-03-31	$7.74M	-3.73%
2015-12-31	$8.04M	1.93%
2015-09-30	$7.89M	-11.50%
2015-06-30	$8.91M	2.57%
2015-03-31	$8.69M	-6.89%
2014-12-31	$9.33M	-4.11%
2014-09-30	$9.73M	-0.22%
2014-06-30	$9.75M	20.47%
2014-03-31	$8.09M	-0.81%
2013-12-31	$8.16M	24.98%
2013-09-30	$6.53M	-7.80%
2013-06-30	$7.08M	-30.97%
2013-03-31	$10.26M	-25.10%
2012-12-31	$13.70M	9.29%
2012-09-30	$12.53M	1.33%
2012-06-30	$12.37M	20.58%
2012-03-31	$10.26M	-21.30%
2011-12-31	$13.03M	-0.17%
2011-09-30	$13.05M	-9.28%
2011-06-30	$14.39M	34.90%
2011-03-31	$10.67M	-16.76%
2010-12-31	$12.81M	5.12%
2010-09-30	$12.19M	13.51%
2010-06-30	$10.74M	6.01%
2010-03-31	$10.13M	-5.45%
2009-12-31	$10.71M	-21.21%
2009-09-30	$13.60M	38.46%
2009-06-30	$9.82M	4.42%
2009-03-31	$9.40M	-4.14%
2008-12-31	$9.81M	14.05%
2008-09-30	$8.60M	2.93%
2008-06-30	$8.36M	0.65%
2008-03-31	$8.30M	11.70%
2007-12-31	$7.43M	-

Cumberland Pharmaceuticals generated $8.29M in revenue during Q3 2025, up -23.48% compared to the previous quarter, and up 84.20% compared to the same period a year ago.

Cumberland Pharmaceuticals Revenue Breakdown

Cumberland Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Product - Other	$4.13M	-	-	-	-
Product	$40.40M	$36.54M	$37.51M	-	-
Product - Vibativ	$9.48M	-	-	-	-
Manufactured Product, Other	-	$1.33M	$2.04M	-	-
Product, Vibativ	-	-	-	$7.49M	$11.70M
Kristalose	-	-	-	$15.21M	$15.99M
Caldolor	-	-	-	$4.83M	$4.97M
Acetadote	-	-	-	$501.04K	$850.99K
Sancuso	-	-	-	$13.21M	-
Vaprisol	-	-	-	$-447.70K	$1.86M
RediTrex	-	-	-	$-126.73K	$55.32K
Omeclamox-Pak	-	-	-	-	$-388.66K

Cumberland Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (74.80%), Product - Vibativ (17.56%), and Product - Other (7.64%).

Quarterly Revenue by Product

Product/Service	Dec 25	Sep 25	Jun 25	Mar 25	Sep 24	Mar 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
Product - Vibativ	$484.87K	$3.00M	$3.00M	$3.00M	$1.03M	$1.61M	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product - Other	$184.62K	$306.51K	$492.39K	$3.14M	$624.20K	$275.33K	-	-	-	-	-	-	-	-	-	-	-	-	-	-
RediTrex	-	-	-	-	-	-	$-122.56K	$9.49K	$-141.04K	$-365.44K	$85.81K	$93.68K	$59.23K	$68.61K	$11.46K	$7.38K	$-32.25K	-	-	-
Sancuso	-	-	-	-	-	-	$1.93M	$1.92M	$1.89M	$2.45M	$3.96M	$3.40M	$3.40M	-	-	-	-	-	-	-
VIBATIV	-	-	-	-	-	-	$2.79M	$2.15M	$1.85M	$1.91M	$1.60M	$2.50M	$325.77K	$399.95K	$1.13M	$2.81M	$3.30M	-	-	-
Vaprisol	-	-	-	-	-	-	-	$23.86K	$16.01K	$-195.64K	$-436.00	$-134.62K	$-117.00K	$-1.55K	$368.73K	$152.78K	$117.19K	$286.41K	$406.16K	$174.16K
Kristalose	-	-	-	-	-	-	$3.89M	$4.11M	$4.32M	$3.79M	$3.90M	$3.57M	$3.95M	$3.71M	$1.26M	$938.33K	$1.54M	$5.18M	$3.62M	$3.48M
Omeclamox-Pak	-	-	-	-	-	-	$23.29K	$8.06K	$-2.52K	$35.60K	$-26.41K	$22.74K	$63.03K	$1.90M	$1.84M	$5.05M	$-383.35K	$516.07K	$10.95K	-
Caldolor	-	-	-	-	-	-	$1.16M	$1.23M	$935.04K	$1.75M	$921.81K	$1.19M	$959.63K	$1.24M	$22.69K	$-24.11K	$-450.26K	$1.66M	$1.42M	$1.17M
Acetadote	-	-	-	-	-	-	$120.05K	$150.16K	$169.86K	$163.35K	$99.79K	$126.79K	$111.09K	$212.29K	$4.01M	$5.28M	$2.99M	$347.03K	$218.46K	$595.31K
Other Products	-	-	-	-	-	-	$299.36K	$1.30M	$197.19K	$496.79K	$480.16K	$295.62K	$178.89K	$461.15K	$182.10K	$265.05K	$874.21K	-	-	-
Grant	-	-	-	-	-	-	-	-	-	-	-	-	$40.00K	$20.00K	$200.00K	$100.00K	$100.00K	$100.00K	-	-

Cumberland Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Product - Vibativ (72.42%), and Product - Other (27.58%).

Cumberland Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Non-US	$4.90M	$2.70M	$1.10M	$1.50M	$2.20M

Cumberland Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 25: Non-US (100.00%).

Cumberland Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
RMTI	Rockwell Medical	$69.26B	$15.93M
NOTV	Inotiv	$513.02M	$120.88M
CPIX	Cumberland Pharmaceuticals	$37.87M	$8.29M
CELU	Celularity	$22.77M	$5.28M
LVTX	LAVA Therapeutics	$11.98M	-
DYAI	Dyadic	$3.09M	$1.16M
ABVC	ABVC BioPharma	$795.95K	-
LTRN	Lantern Pharma	-	-
RVPH	Reviva Pharmaceuticals	-	-
CALC	CalciMedica	-	-
QNTM	Quantum BioPharma	-	-

CPIX Revenue FAQ

What is Cumberland Pharmaceuticals’s yearly revenue?

Cumberland Pharmaceuticals's yearly revenue for 2024 was $37.87M, representing a decrease of -4.26% compared to 2023. The company's yearly revenue for 2023 was $39.55M, representing a decrease of -5.85% compared to 2022. CPIX's yearly revenue for 2022 was $42.01M, representing an increase of 16.75% compared to 2021.

What is Cumberland Pharmaceuticals’s quarterly revenue?

Cumberland Pharmaceuticals's quarterly revenue for Q3 2025 was $8.29M, a -23.48% decrease from the previous quarter (Q2 2025), and a -8.73% decrease year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $10.84M, a -7.48% decrease from the previous quarter (Q1 2025), and a 10.04% increase year-over-year (Q2 2024). CPIX's quarterly revenue for Q1 2025 was $11.71M, a 12.24% increase from the previous quarter (Q4 2024), and a 37.84% increase year-over-year (Q1 2024).

What is Cumberland Pharmaceuticals’s revenue growth rate?

Cumberland Pharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was -9.86%, and for the last 5 years (2020-2024) was 1.14%.

What are Cumberland Pharmaceuticals’s revenue streams?

Cumberland Pharmaceuticals's revenue streams in c 25 are Product - Other, Product, and Product - Vibativ. Product - Other generated $4.13M in revenue, accounting 7.64% of the company's total revenue Product generated $40.4M in revenue, accounting 74.80% of the company's total revenue, up 10.56% year-over-year. Product - Vibativ generated $9.48M in revenue, accounting 17.56% of the company's total revenue

What is Cumberland Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Cumberland Pharmaceuticals was Product. This segment made a revenue of $40.4M, representing 74.80% of the company's total revenue.